Regulus Therapeutics Inc. (RGLS) Covered Calls

Regulus Therapeutics Inc. covered calls Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering & developing drugs that target micro RNAs to treat a range of diseases.

You can sell covered calls on Regulus Therapeutics Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RGLS (prices last updated Fri 4:16 PM ET):

Regulus Therapeutics Inc. (RGLS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.43 -0.07 1.41 1.48 256K - 0.1
Covered Calls For Regulus Therapeutics Inc. (RGLS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 1 0.00 1.48 -32.4% -328.5%
Jan 17 1 0.00 1.48 -32.4% -184.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Regulus Therapeutics, Inc. discovers and develops pharmaceutical products. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The company intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. It is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection. Regulus Therapeutics was founded in September 2007 and is headquartered in San Diego, CA.